Eli Lilly Talks Up Emerging Markets, Especially China, As One Salve For Its Problems
This article was originally published in PharmAsia News
Executive Summary
Insisting they are not playing catch up overseas, Eli Lilly executives outlined plans for growing their business in the so-called emerging markets that are now a hot terrain - and a familiar phrase - among the biggest drug makers
You may also be interested in...
Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China
Facing a looming patent cliff, Japan's Takeda made good on a pledge to dive into emerging markets by signing a co-promotion deal with Pfizer to market its type 2 Actos diabetes drug in China
Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China
Facing a looming patent cliff, Japan's Takeda made good on a pledge to dive into emerging markets by signing a co-promotion deal with Pfizer to market its type 2 Actos diabetes drug in China
Eli Lilly Global External R&D Director Yetunde Taiwo On Partnering Plans For Discovery Research: An Interview With PharmAsia News
Yetunde Taiwo, Eli Lilly's global external R&D director, is on a global hunt for molecules that can bolster Lilly's research efforts and arm it with novel therapies. Eli Lilly spends more than $3.4 billion on research every year and prides itself on being a pioneer in collaborating with scientists to bring drugs into the market. Over the last two years, Eli Lilly struck research alliances with at least four Indian companies and has increased its activities in Asia (PharmAsia News, Oct 27, 2008). Taiwo sat down with PharmAsia News' India bureau to give a lowdown on Lilly's risk-sharing strategy to shore up its new chemical entities.
Need a specific report? 1000+ reports available
Buy Reports